Endo International plc (ENDPQ)

Market Cap	1.91M
Revenue (ttm)	2.16B
Net Income (ttm)	-942.82M
Shares Out	235.22M
EPS (ttm)	-4.00
PE Ratio	n/a
Forward PE	0.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	195,072
Open	0.0081
Previous Close	0.0100
Day's Range	0.0080 - 0.0099
52-Week Range	0.0080 - 0.1600
Beta	1.35
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 27, 2023

About ENDPQ

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PE...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Sep 25, 1996
• Employees: 2,861
• Stock Exchange: OTCMKTS
• Ticker Symbol: ENDPQ

Financial Performance

In 2022, ENDPQ's revenue was $2.32 billion, a decrease of -22.53% compared to the previous year's $2.99 billion. Losses were -$2.91 billion, 411.3% more than in 2021.